StockNews.AI
AZN
StockNews.AI
217 days

AstraZeneca PLC Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights - AZN

1. A class action lawsuit targets AstraZeneca for alleged securities fraud. 2. Lawsuit claims AstraZeneca's fraudulent activities have significant legal implications. 3. Investors may seek compensation due to losses during the specified period. 4. The China President's detention heightens the company's legal risks. 5. Non-lead plaintiffs can partake without costs, increasing investor participation.

4m saved
Insight
Article

FAQ

Why Bearish?

The legal implications from the fraud allegations could reduce investor confidence.

How important is it?

Significant lawsuits can directly impact stock prices and investor sentiment.

Why Short Term?

Law litigation can lead to immediate stock price fluctuations, seen in past cases.

Related Companies

NEW YORK, Jan. 14, 2025 /PRNewswire/ --

Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit.

CLASS DEFINITION:

The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=122514&wire=4

AZN investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS:

The filed complaint alleges that defendants made false statements and/or concealed that: (1) AstraZeneca engaged in insurance fraud in China; (2) as a result, AstraZeneca faced heightened legal exposure in China, which eventually resulted in the AstraZeneca China President being detained by Chinese law enforcement authorities; (3) as a result, AstraZeneca understated its legal risks; (4) the foregoing, once revealed, could materially harm AstraZeneca's business activities in China; and (5) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

WHAT'S NEXT?

If you suffered a loss in AstraZeneca during the relevant time frame, you have until February 21, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU:

If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY:

Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE Levi & Korsinsky, LLP

Related News